Arimidex is the brand name for anastrozole, a tablet that blocks the enzyme aromatase and therefore lowers estradiol. It was approved for breast cancer in postmenopausal women, and it is used off label by men who want to control estrogen on a cycle or during testosterone therapy.
It is also the drug most often misused in that setting, because the goal is not to remove estrogen but to keep it in range. This guide covers what the label says, how the drug behaves in the body, and what goes wrong when the dose is too high.
Key facts about Arimidex
| Active substance | Anastrozole |
| Drug class | Nonsteroidal aromatase inhibitor |
| Molecular formula | C17H19N5, molecular weight 293.4 |
| Tablet strength | 1 mg, taken once daily in the labelled use |
| Half-life | About 46.8 hours |
| Labelled use | Hormone receptor positive breast cancer in postmenopausal women |
| Use in men | Off label, no approved male indication |
| Main risks in the label | Bone density loss, cholesterol rise, cardiovascular events, fetal harm |
What anastrozole is
Anastrozole is a nonsteroidal aromatase inhibitor, a small molecule that binds the aromatase enzyme and stops it from converting testosterone and androstenedione into estradiol and estrone. It is not a steroid, not a SERM, and it does not block estrogen receptors. It reduces how much estrogen the body makes, which is a different mechanism from tamoxifen or clomiphene.
That distinction matters in practice. A SERM blocks the receptor and leaves circulating estradiol high, which is why clomiphene can raise testosterone while estrogen numbers stay elevated. An aromatase inhibitor lowers the number itself.
How aromatase inhibition works
Aromatase is the enzyme that performs the last step of estrogen synthesis, converting androgens to estrogens in fat tissue, muscle, bone and the brain. Men need estrogen as well as testosterone: estradiol is involved in bone density, libido, mood and joint comfort, and it also participates in the feedback loop that limits testosterone production.
Block the enzyme and three things follow:
- estradiol falls, sometimes sharply
- testosterone rises slightly, because less of it is being converted
- the feedback signal to the pituitary changes, which can affect luteinizing hormone
Whether that is useful or harmful depends entirely on where estradiol started and how far it falls. There is no benefit in driving it to zero.
Bone density, cholesterol, cardiovascular events and fetal harm. All four appear in the approved label.
What the label covers
The approved indications are specific to women: adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer, and first line treatment of locally advanced or metastatic disease in the same group. The dose is 1 mg once daily, and the measured half-life is about 46.8 hours.
| Label warning | What it means for the patient |
|---|---|
| Decreased bone mineral density | Bone density monitoring is advised, because estrogen is protective for bone |
| Increases in total cholesterol | Cholesterol monitoring is advised |
| Ischemic cardiovascular events | Increased incidence compared with tamoxifen in women with existing ischemic heart disease |
| Embryo-fetal toxicity | The drug can harm a fetus, contraception is advised |
Read that table again and notice what it implies for a man using the drug for months at a time: the three main safety signals in the label are bone, lipids and the cardiovascular system. All three are estrogen dependent.
Use in men: what is established
There is no approved male indication. What exists is clinical experience in two narrow situations and a much wider grey market use in bodybuilding.
In clinical practice, aromatase inhibitors appear in the management of gynecomastia and in selected cases of hormone therapy, where the goal is a measured estradiol level rather than a guessed one. The 2026 clinical practice guidelines on gynecomastia from the Italian Society of Andrology and Sexual Medicine frame medical therapy carefully, restrict testosterone replacement to men with proven hypogonadism, and reserve surgery for long standing fibrotic cases or significant psychological distress. That is the standard of care: targeted, monitored, and not a routine add on to every cycle.
Anastrozole moves estradiol down the scale. How far depends on body fat, the aromatizable dose and individual enzyme activity.
Both ends of the scale produce symptoms. Low estrogen gives aching joints, flat mood and falling HDL. High estrogen gives water retention, nipple sensitivity and rising blood pressure. Only a sensitive estradiol assay tells you where you are.
Low estrogen: the real risk
The most common mistake is treating aromatase inhibitors as a safety blanket: take one every cycle, keep the dose fixed, never measure anything. Estradiol is not a waste product. When it drops too far, the symptoms are predictable:
| System | What low estradiol looks like |
|---|---|
| Joints | Aching, clicking, a feeling of dryness in knees and shoulders |
| Libido and erections | Loss of interest and weaker erections, often blamed on the steroid instead |
| Mood and energy | Flat mood, irritability, poor sleep |
| Lipids | HDL falls further, which compounds the effect of the cycle itself |
| Bone | Loss of density over months, which is why the label advises monitoring |
None of these appear on day one. They build over weeks, and because they overlap with the side effects of the cycle, they are easy to misattribute. The only way to tell whether estrogen is too high or too low is to measure it.
Tablets, splitting and dosing reality
The tablet is 1 mg, which is a large dose for male use, and the tablets are not scored. The three drugs that do this job, anastrozole, exemestane and tamoxifen, all sit in cycle support. That is the origin of the folklore about quartering tablets with a knife and getting uneven pieces. Two practical points follow.
| Reality | Consequence |
|---|---|
| Only 1 mg tablets are manufactured | Any male dose is a fraction, and fractions are imprecise by hand |
| Half-life is about 47 hours | Daily dosing is not the only option, but skipping days makes levels swing |
| No validated male dose exists | Any schedule is a guess until your own blood work says otherwise |
| Response varies widely | Body fat, dose of aromatizable steroid and individual aromatase activity all change the result |
If a doctor is involved, the sensible pattern is a baseline estradiol, a low starting exposure, a repeat measurement after two to three weeks, and adjustment from there. If nobody is involved, the honest statement is that you are experimenting on yourself without a control.
Blood work and monitoring
| Marker | Why it matters with an aromatase inhibitor | When |
|---|---|---|
| Estradiol, sensitive assay | The whole point; standard assays are unreliable at low male levels | Baseline, week 2 to 3, then as needed |
| Total and free testosterone | Removing the estrogen brake can raise testosterone, changing the cycle | Baseline and mid cycle |
| Lipid panel | HDL falls with low estradiol, and the label warns about cholesterol | Baseline and week 6 |
| Bone density, long term | The label advises monitoring because density can drop | Before long term use, then periodically |
| Blood pressure and resting heart rate | Cardiovascular signals are the ones the label takes most seriously | Weekly |
Frequently Asked Questions
Where this fits on this site
Anastrozole belongs with the other support drugs in the cycle support category, next to tamoxifen and clomiphene. If you are planning recovery rather than estrogen control, start with the guide to post cycle therapy and the article on Clomid for men. To understand where estrogen comes from in the first place, read the Anavar guide, where the non aromatizing route is explained from the other side.
- PubChem compound summary for anastrozole, CID 2187: molecular formula C17H19N5, molecular weight 293.4
- DailyMed label, anastrozole tablets 1 mg: indications, once daily dosing, half-life 46.8 hours, and the bone, lipid, cardiovascular and fetal warnings
- Management of gynecomastia in adolescence and adults: clinical practice guidelines, Italian Society of Andrology and Sexual Medicine, 2026. PMID 42258023
- Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives, Endocrine Connections, 2026. PMID 42644333
Medical disclaimer. This article is informational and does not replace advice from a licensed physician. Anastrozole has no approved male indication, and lowering estradiol without monitoring carries measurable risks to bone, lipids and the cardiovascular system.